(-)-epigallocatechin 3-gallate/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases glycated haemoglobin (HbA1c)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Notably, the reduction in HbA1c (WMD: -0.18%, 95% CI: -0.35, -0.02; P = 0.029) was small and may not equate to clinically meaningful benefits for all populations.”
Quoted verbatim from Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- Pooled across 41 randomized controlled trials of EGCG supplementation (meta-analysis of glycemic index and related parameters).
Effect -0.18 mean difference, 95% CI -0.35 to -0.02
Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2025PMID:40885603Permalink
Keep reading
- Everything the graph holds on (-)-epigallocatechin 3-gallate
- Every compound studied against Glycated haemoglobin (HbA1c)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M1JGKK14CMQJFMATTBDTA2CT